According to GuruFocus' list, these stocks have reached their 52-week highs.
Exelon reached the 52-week high of $51.95
Exelon Corp. (EXCU, Financial) is one of the largest power retailers engaged in the utilities sector of the U.S. The company is involved in power generation and transmission activities.
Since acquiring Pepco in 2016, Exelon serves more customers than any other U.S. utility with 10 million power and gas customers at its six regulated utilities in Illinois, Pennsylvania, Maryland, New Jersey, Delaware and Washington, D.C. Exelon owns 11 nuclear plants and 33 gigawatts of generation capacity throughout North America, producing 20% of U.S. nuclear power and 5% of all U.S. electricity. The company is the largest power retailer in the U.S., serving about 200 terawatt hours of load.
The price of Exelon shares has reached $51.95, which is 0.8% off the 52-week high of $52.36. Exelon has a market cap of $33.16 billion; its shares were traded around $51.95 with a price-earnings (P/E) ratio of 19.91 and a price-sales (P/S) ratio of 1.06.
Exelon's trailing 12-month dividend yield is 1.56%. The forward dividend yield is 6.26%.
Exelon's GAAP net income for the second quarter dropped to 9 cents per share from 29 cents per share in the second quarter of 2016; adjusted (non-GAAP) operating earnings declined to 54 cents per share in the second quarter from 65 cents per share in the second quarter of 2016.
Baxalta reached the 52-week high of $45.95
Baxalta Inc. (BXLT, Financial) is engaged in developing and marketing biopharmaceuticals. The company offers biopharmaceuticals for the treatment of hemophilia, bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency and other chronic conditions.
Baxalta was incorporated on Sept. 8, 2016. It is a biopharmaceutical company engaged in the field of unmet medical needs covering various diseases including hemophilia, immunology and oncology. The company develops, manufactures and markets a diverse portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock and other chronic and acute medical conditions as well as oncology treatments.
The price of Baxalta shares has reached $45.95, which is 1.2% off the 52-week high of $46.52. Baxalta has a market cap of $30.87 billion; its shares were traded around $45.95.
Baxalta's trailing 12-month dividend yield is 0.46%. The forward dividend yield is 0.61%.
In the first quarter, Baxalta generated net income on a GAAP basis of $145 million and earnings of 21 cents per diluted share. These results include net after-tax special items totaling $181 million, or 26 cents per diluted share. On an adjusted basis, excluding special items, Baxalta reported first quarter net income of $326 million, or 47 cents per diluted share, which compares favorably to the company’s previously issued guidance of 44 cents to 46 cents per diluted share.
Home Depot reached the 52-week high of $159.66
The Home Depot Inc. (HD, Financial) is a home improvement specialty retailer. Its stores sell an assortment of building materials, home improvement and lawn and garden products and provide a number of services.
Home Depot is the world's largest home improvement specialty retailer, operating nearly 2,300 warehouse-format stores throughout the U.S., Canada and Mexico. The firm's stores offer products and services for home construction, renovation, remodeling and maintenance. The acquisition of direct marketer and distributor Interline Brands in 2015 allowed the company to enter the maintenance, repair and operations sector.
The price of Home Depot shares has reached $159.66, which is 0.8% off the 52-week high of $160.86. Home Depot has a market cap of $188.21 billion; its shares were traded around $159.66 with a P/E ratio of 22.94 and P/S ratio of 1.97.
Home Depot's trailing 12-month dividend yield is 2.10%. The forward dividend yield is 2.23%. Home Depot had an annual average earnings growth of 11.50% over the past 10 years.
The company recently reported sales of $28.1 billion for the second quarter of fiscal 2017, a 6.2% increase from the second quarter of fiscal 2016. Net earnings for the second quarter were $2.7 billion, or $2.25 per diluted share, compared with net earnings of $2.4 billion, or $1.97 per diluted share, in the same period of fiscal 2016. For the second quarter of fiscal 2017, diluted earnings per share increased 14.2% from the same period in the prior year.
Executive Vice President and Chief Information Officer Matt Carey sold 32,000 shares for $157.1 per share on Sept. 7. The stock price has increased by 1.63% since.
Cigna reached the 52-week high of $184.56
Cigna Corp. (CI, Financial) operates in the health care industry. It provides medical, dental, disability, life and accident insurance products.
Cigna is one of the largest managed-care organizations in the U.S. with a little over 14 million medical members. The firm provides health insurance services to individuals mainly through the group (employer) market. Cigna is one of the leaders in the commercial self-funded fee market, from which most of the growth has and will continue to come, for the large-group segment. The firm also participates in other insurance and retirement businesses that make up a material portion of its total operations.
The price of Cigna shares has reached $184.56, which is 0.5% off the 52-week high of $185.51. Cigna has a market cap of $46.47 billion; its shares were traded around $184.56 with a P/E ratio of 21.24 and P/S ratio of 1.18.
Cigna's trailing 12-month dividend yield is 0.02%. The forward dividend yield is 0.02%. Cigna had an annual average earnings growth of 14.80% over the past 10 years. GuruFocus rated Cigna the business predictability rank of 4.5 stars.
The company recently reported that total revenues in the second quarter were $10.3 billion, an increase of 4% over second quarter 2016, driven by continued growth in Cigna's targeted customer segments. For the second quarter, shareholders’ net income was $813 million, or $3.15 per share, compared with $510 million, or $1.97 per share, for the second quarter of 2016. Cigna's adjusted income from operations for the second quarter was $750 million, or $2.91 per share, compared with $515 million, or $1.98 per share, for the second quarter of 2016. This reflects significantly increased earnings contributions from each of our business segments.
Executive Vice President, Global Chief Marketing and Customer Officer Lisa R. Bacus sold 2,236 shares for $179.95 per share on Aug. 16. The stock price has increased by 2.56% since.
Stanley Black & Decker reached the 52-week high of $147.05
Stanley Black & Decker Inc. (SWK, Financial) provides hand tools, power tools and accessories, mechanical access solutions, electronic security and monitoring systems, health care solutions, engineered fastening systems and products for various industrial applications.
Stanley Black & Decker is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end users, distributors, retail consumers and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the U.S.
The price of Stanley Black & Decker shares has reached $147.05, which is 0.9% off the 52-week high of $148.32. Stanley Black & Decker has a market cap of $22.52 billion; its shares were traded around $147.05 with a P/E ratio of 18.86 and P/S ratio of 1.87.
Stanley Black & Decker's trailing 12-month dividend yield is 1.61%. The forward dividend yield is 1.71%. Stanley Black & Decker had an annual average earnings growth of 5.90% over the past 10 years.
The company recently announced second-quarter revenues totaled $3.2 billion, up 10% versus the prior year, with strong organic growth of 7%. Second-quarter operating margin rate was 14.7%. Excluding M&A-related charges, operating margin rate was 15.7%. Second-quarter diluted GAAP EPS was $1.82. Excluding M&A-related charges, second-quarter diluted EPS was $2.01, up 9% versus the prior year, reflecting strong operational performance.
Disclosure: I do not own these stocks.
